Cat. No：GM-C16925
Product：H_FCGR2B CHO-K1 Cell Line
Cat. No：GM-C16925
Product：H_FCGR2B CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
H_FCGR2B(CD32b) amino acid sequence (P31994-1)：
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWINVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPNFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAAVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDALEEPDDQNRI
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line | H_FCGR3A(CD16a) 158V CHO-K1 Cell Line |
| H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line | H_FcRn MDCK Cell Line |
| Mouse_FcRn MDCK Cell Line | ||
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line |
| ADCP FcγRIIa Jurkat Effector Cell Line | ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line |
Li Q, Zhang K, Yu Y, Yu Z, Xu J, Shen W, Zhang L, Qu A, Liang H. TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma. PLoS One. 2024 Sep 25;19(9):e0310889. doi: 10.1371/journal.pone.0310889. PMID: 39321199; PMCID: PMC11423992.
Cat. No：GM-C16925
Product：H_FCGR2B CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
H_FCGR2B(CD32b) amino acid sequence (P31994-1)：
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWINVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPNFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAAVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDALEEPDDQNRI
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line | H_FCGR3A(CD16a) 158V CHO-K1 Cell Line |
| H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line | H_FcRn MDCK Cell Line |
| Mouse_FcRn MDCK Cell Line | ||
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line |
| ADCP FcγRIIa Jurkat Effector Cell Line | ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line |
Li Q, Zhang K, Yu Y, Yu Z, Xu J, Shen W, Zhang L, Qu A, Liang H. TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma. PLoS One. 2024 Sep 25;19(9):e0310889. doi: 10.1371/journal.pone.0310889. PMID: 39321199; PMCID: PMC11423992.
